HOUSTON, Sept. 17 /PRNewswire-FirstCall/ -- Cyberonics, Inc. (Nasdaq: CYBX) today announced, as required under NASDAQ Listing Rule 5635(c)(4), that the Compensation Committee of its Board of Directors approved an award from its Amended and Restated New Employee Equity Inducement Plan of 800 shares of restricted stock and an option to purchase 2,000 shares of its common stock for $24.55 per share, the closing price of the company’s stock on September 15, 2010, the date of the award, to Melissa Farina, the company’s new Director, International Finance. Twenty-five percent of the shares subject to the award will vest on each of the first four anniversaries of the grant date.
About Cyberonics, Inc. and VNS Therapy®
Cyberonics, Inc. (NASDAQ:CYBX) is a medical technology company with core expertise in neuromodulation. The company developed and markets the Vagus Nerve Stimulation (VNS) Therapy System, which is FDA-approved for the treatment of refractory epilepsy and treatment-resistant depression. The VNS Therapy System uses a surgically implanted medical device that delivers pulsed electrical signals to the vagus nerve. Cyberonics markets the VNS Therapy System in approximately 70 countries worldwide, and to date more than 60,000 patients have been implanted with the device.
Additional information on Cyberonics and VNS Therapy is available at www.cyberonics.com.
CONTACT INFORMATION: | |
Greg Browne, CFO | |
Cyberonics, Inc. | |
100 Cyberonics Blvd. | |
Houston, TX 77058 | |
Main: (281) 228-7262 | |
Fax: (281) 218-9332 | |
SOURCE Cyberonics, Inc.
